PLATINUM-RESISTANT OVARIAN CARCINOMA
Clinical trials for PLATINUM-RESISTANT OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PLATINUM-RESISTANT OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for PLATINUM-RESISTANT OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for women with Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study is testing if a new drug called PLX038 can shrink tumors in people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to standard platinum-based chemotherapy. The drug works by blocking enzymes that cancer cells need to grow…
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope: using a Patient's own supercharged cells to battle aggressive ovarian cancer
Disease control Recruiting nowThis early-stage study is testing a new personalized treatment for ovarian cancer that has returned or stopped responding to standard therapies. Doctors take a patient's own immune cells, grow and train them in a lab to recognize cancer, and then infuse them back into the patient…
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Old drug, new hope: infection fighter takes on resistant ovarian cancer
Disease control Recruiting nowThis study is testing whether atovaquone, a medication normally used to treat certain infections, can help control ovarian cancer that has stopped responding to standard platinum chemotherapy. It will involve 28 patients with this resistant form of cancer to see if the drug can s…
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
Scientists test new drug duo to target Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two oral drugs, M1774 and ZEN-3694, for women with recurrent ovarian or endometrial cancer. The main goals are to find the safest and most effective dose and to see how well the drugs work together to stop cancer cell growth.…
Matched conditions: PLATINUM-RESISTANT OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC